Last reviewed · How we verify
Taxotere (docetaxel)
Taxotere (docetaxel) works by inhibiting cell division, ultimately leading to cell death in rapidly dividing cancer cells.
Taxotere (docetaxel) works by inhibiting cell division, ultimately leading to cell death in rapidly dividing cancer cells. Used for Breast cancer, Non-small cell lung cancer, Prostate cancer.
At a glance
| Generic name | Taxotere (docetaxel) |
|---|---|
| Also known as | Docetaxel, Taxotere |
| Sponsor | Seagen Inc. |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel binds to tubulin, preventing the formation of microtubules and disrupting the mitotic spindle, which is essential for cell division. This leads to cell cycle arrest and apoptosis in cancer cells.
Approved indications
- Breast cancer
- Non-small cell lung cancer
- Prostate cancer
- Stomach cancer
- Head and neck cancer
Common side effects
- Neutropenia
- Anemia
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (PHASE3)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer (PHASE2)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taxotere (docetaxel) CI brief — competitive landscape report
- Taxotere (docetaxel) updates RSS · CI watch RSS
- Seagen Inc. portfolio CI